Evaluation of Anemia Management in Hemodialysis Patients at Nephrology Diagnostic and Treatment Hospital
DOI:
https://doi.org/10.26719//-05.18.2.08Keywords:
Pharmacies, Pharmacists, Patient Safety, Dispensing, LibyaAbstract
Purpose: This research aimed to evaluate how anemia is handled in hemodialysis patients and identify risk factors. Methods: This study involved analyzing the current approach to managing anemia in a nephrology hospital, comparing it to KDOQI guidelines. It was conducted in a hospital specializing in the diagnosis and treatment of kidney diseases. In Tripoli, Libya, documents were randomly selected between October 2023 and May 2024. There were 89 patients receiving hemodialysis in total. Analysis of data was performed using SPSS Version 26. Results: Data on age distribution revealed that the largest age group consisted of individuals aged 56-65 years, comprising 39 patients (43.8%), closely trailed by the age range of 36-55 years, with 37 patients (41.6%). The average age was 53.56 years and there was a male to female ratio of 1.7:1. The results of the study showed that most patients (59.6%) had a mean Hgb value below 10, while 21.3% had a mean Hgb value between 10 and 10.9. Additionally, only ≥11 cases reported a percentage of 19.1% and also stated that the average Hgb value was 9.716. Conclusions: This study reveals that anemia isunsatisfactorily controlled in hemodialysis patients. ESA hyporesponsivness played a critical role in lowering hemoglobin levels in the current therapeuticstrategies used.
Downloads
References
WORLD HEALTH RANKINGS. Libya: Kidney Disease. 2020; Available from: https://www.worldlifeexpectancy.com/libya-kidney-disease.
Murtagh, F.E., J. Addington-Hall, and I.J. Higginson, The prevalence of symptoms in end-stage renal disease: a systematic review. Advances in chronic kidney disease, 2007. 14(1): p. 82-99.
Jiang, J., et al., The impact of short daily hemodialysis on anemia and the quality of life in Chinese patients. Brazilian Journal of Medical and Biological Research, 2013. 46(7): p. 629-633.
Suzuki, M., et al., Effects of anemia correction by erythropoiesis-stimulating agents on cardiovascular function in non-dialysis patients with chronic kidney disease. International heart journal, 2012. 53(4): p. 238-243.
Pınarbaşı, A.S., et al., Erythropoietin resistance index and the affecting factors in children with peritoneal dialysis. Blood Purification, 2021. 50(6): p. 942-951.
Mikhail, A., et al., Renal association clinical practice guideline on Anaemia of Chronic Kidney Disease. BMC nephrology, 2017. 18: p. 1-29.
Martinez-Vea, A., et al., Role of oxidative stress in cardiovascular effects of anemia treatment with erythropoietin in predialysis patients with chronic kidney disease. Clinical nephrology, 2012. 77(3): p. 171-181.
Go, A.S., et al., Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. New England Journal of Medicine, 2004. 351(13): p. 1296-1305.
Silverberg, D.S., et al., The effect of correction of anaemia in diabetics and non‐diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron. Nephrology Dialysis Transplantation, 2003. 18(1): p. 141-146.
Al-Jabi, S.W., et al., A multicenter descriptive analysis of anemia management in hemodialysis patients and its association with quality of life. BMC nephrology, 2023. 24(1): p. 197.
Al-Ageel, N.A., et al., Appropriateness of anemia management in hemodialysis patients. Saudi Pharmaceutical Journal, 2012. 20(1): p. 85-91.
Akel, M., et al., Evaluation of the management of anemia in hemodialysis patients in Lebanon. Journal of Nephropharmacology, 2017. 6(2): p. 68-73.
Lizardi Gómez, L., et al., Factors related to the presence of anemia in patients with chronic kidney disease in hemodialysis. Annals of Hematology and Oncology, 2021. 8(1): p. 1326.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Zeineb Alsharef, Ahmed Abired , Taha Elsheredi (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Open Access Policy
Libyan journal of medical Research (LJMR).is an open journal, therefore there are no fees required for downloading any publication from the journal website by authors, readers, and institution.
The journal applies the license of CC BY (a Creative Commons Attribution 4.0 International license). This license allows authors to keep ownership f the copyright of their papers. But this license permits any user to download , print out, extract, reuse, archive, and distribute the article, so long as appropriate credit is given to the authors and the source of the work.
The license ensures that the article will be available as widely as possible and that the article can be included in any scientific archive.
Editorial Policy
The publication of an article in a peer reviewed journal is an essential model for Libyan journal of medical Research (LJMR). It is necessary to agree upon standards of expected ethical behavior for all parties involved in the act of publishing: the author, the journal editorial, the peer reviewer and the publisher.
Any manuscript or substantial parts of it, submitted to the journal must not be under consideration by any other journal. In general, the manuscript should not have already been published in any journal or other citable form, although it may have been deposited on a preprint server. Authors are required to ensure that no material submitted as part of a manuscript infringes existing copyrights, or the rights of a third party.
Authorship Policy
The manuscript authorship should be limited to those who have made a significant contribution and intellectual input to the research submitted to the journal, including design, performance, interpretation of the reported study, and writing the manuscript. All those who have made significant contributions should be listed as co-authors.
Others who have participated in certain substantive aspects of the manuscript but without intellectual input should only be recognized in the acknowledgements section of the manuscript. Also, one of the authors should be selected as the corresponding author to communicate with the journal and approve the final version of the manuscript for publication in the LJMR.
Peer-review Policy
- All the manuscripts submitted to LJMR will be subjected to the double-blinded peer-review process;
- The manuscript will be reviewed by two suitable experts in the respective subject area.
- Reports of all the reviewers will be considered while deciding on acceptance/revision or rejection of a manuscript.
- Editor-In-Chief will make the final decision, based on the reviewer’s comments.
- Editor-In-Chief can ask one or more advisory board members for their suggestions upon a manuscript, before making the final decision.
- Associate editor and review editors provide administrative support to maintain the integrity of the peer-review process.
- In case, authors challenge the editor’s negative decision with suitable arguments, the manuscript can be sent to one more reviewer and the final decision will be made based upon his recommendations.
